中国医学创新
中國醫學創新
중국의학창신
MEDICAL INNOVATION OF CHINA
2015年
5期
45-47,48
,共4页
食管癌%同步放化疗%序贯化放疗
食管癌%同步放化療%序貫化放療
식관암%동보방화료%서관화방료
Esophageal carcinoma%Concurrent chemotherapy%Radiotherapy
目的：研究同步与序贯化放疗在食管癌治疗中的临床效果和安全性，找到治疗食管癌的最佳方法，降低复发率，有效提高癌症的生存率。方法：选取本院2011年6月-2014年6月收治的食管癌患者100例，将其作为临床研究对象，采用随机数字表法将其分为两组，对照组采用序贯化放疗进行治疗，即在两个疗程化疗后进行放疗；试验组采用同步化放疗进行治疗，即在治疗的第1天起同时进行化疗和放疗，对比两组的临床疗效，同时对治疗过程中出现的不良反应进行详细记录后对比分析，出院后对所有参加本次实验的患者进行为期3年的随访。结果：试验组显效20例，有效28例，无效2例，总有效率为96.00%，对照组显效15例，有效20例，无效15例，总有效率为70.00%，两组比较差异有统计学意义（P<0.05）。试验组不良反应发生率为56.00%，对照组为50.00%，两组比较差异无统计学意义（P>0.05）。结论：采用同步化放疗治疗食管癌的临床效果较为明显，治疗过程中出现的不良反应高于序贯化放疗，但不良反应均在患者可承受的范围内，整个过程未出现严重后果，安全可靠，患者以及患者家属较为满意，因此值得在临床上进行继续探讨和广泛应用。
目的：研究同步與序貫化放療在食管癌治療中的臨床效果和安全性，找到治療食管癌的最佳方法，降低複髮率，有效提高癌癥的生存率。方法：選取本院2011年6月-2014年6月收治的食管癌患者100例，將其作為臨床研究對象，採用隨機數字錶法將其分為兩組，對照組採用序貫化放療進行治療，即在兩箇療程化療後進行放療；試驗組採用同步化放療進行治療，即在治療的第1天起同時進行化療和放療，對比兩組的臨床療效，同時對治療過程中齣現的不良反應進行詳細記錄後對比分析，齣院後對所有參加本次實驗的患者進行為期3年的隨訪。結果：試驗組顯效20例，有效28例，無效2例，總有效率為96.00%，對照組顯效15例，有效20例，無效15例，總有效率為70.00%，兩組比較差異有統計學意義（P<0.05）。試驗組不良反應髮生率為56.00%，對照組為50.00%，兩組比較差異無統計學意義（P>0.05）。結論：採用同步化放療治療食管癌的臨床效果較為明顯，治療過程中齣現的不良反應高于序貫化放療，但不良反應均在患者可承受的範圍內，整箇過程未齣現嚴重後果，安全可靠，患者以及患者傢屬較為滿意，因此值得在臨床上進行繼續探討和廣汎應用。
목적：연구동보여서관화방료재식관암치료중적림상효과화안전성，조도치료식관암적최가방법，강저복발솔，유효제고암증적생존솔。방법：선취본원2011년6월-2014년6월수치적식관암환자100례，장기작위림상연구대상，채용수궤수자표법장기분위량조，대조조채용서관화방료진행치료，즉재량개료정화료후진행방료；시험조채용동보화방료진행치료，즉재치료적제1천기동시진행화료화방료，대비량조적림상료효，동시대치료과정중출현적불량반응진행상세기록후대비분석，출원후대소유삼가본차실험적환자진행위기3년적수방。결과：시험조현효20례，유효28례，무효2례，총유효솔위96.00%，대조조현효15례，유효20례，무효15례，총유효솔위70.00%，량조비교차이유통계학의의（P<0.05）。시험조불량반응발생솔위56.00%，대조조위50.00%，량조비교차이무통계학의의（P>0.05）。결론：채용동보화방료치료식관암적림상효과교위명현，치료과정중출현적불량반응고우서관화방료，단불량반응균재환자가승수적범위내，정개과정미출현엄중후과，안전가고，환자이급환자가속교위만의，인차치득재림상상진행계속탐토화엄범응용。
Objective:To study clinical therapeutic effect of the simultaneous and sequential chemoradiotherapy in patients with esophageal carcinoma and safety,to find the best method of treatment of esophageal cancer,reduce the recurrence rate,improve the survival rate of cancer.Method:100 patients with esophageal cancer in our hospital from June 2011 to June 2014 selected the cases admitted as the clinical research object,randomly divided into two groups, the control group were treated with radiotherapy,namely in the two course of chemotherapy,radiotherapy;the test group was treated with concurrent chemoradiotherapy treatment at the same time,namely the chemotherapy and radiotherapy on the first day of treatment,were compared after treatment,compared to patients with clinical curative effect,and adverse reactions during the treatment of the contrast and analysis of the detailed record,after discharge for a period of three years of follow-up for all patients participating in this experiment.Result:The test group with concurrent chemoradiotherapy treatment markedly 20 cases,effective 28 cases,invalid 2 cases,the total effective was 96.00%,the control group used sequential chemoradiotherapy for treatment of 15 cases markedly effective,effective 20 cases,invalid 15 cases,the total effective was 70.00%,the difference between the two groups was statistically significant(P<0.05).The rate of adverse reactions occurred in test group 56.00%,control group of adverse reaction in 50.00%,differences between the two groups was not statistically significant(P>0.05).Conclusion:Using the clinical effect of concurrent chemoradiotherapy in the treatment of esophageal carcinoma is more obvious,adverse reactions during treatment was higher than that of sequential chemoradiotherapy,but adverse reactions were in the range of patients can bear,serious consequences,not the whole process is safe and reliable,patients and family members of patients more satisfied,so it is worthy for us to continue to explore and wide in the clinical application.
